MDS Current Trials UK

We aim to list an easily understandable description of any MDS clinical trials currently opened to recruitment in the UK.

Patients will be able to read up on the details of these trials and use this information to discuss with their consultants or nurses.

Not all patients can be enrolled in drug trials - as not every patient will fit the necessary inclusion criteria, which need to be followed very strictly. However, if a particular clinical trial drug is considered an option by the haematologist, it is sometimes possible to obtain the drug outside the trial, on the basis of compassionate use.

All the trials listed in this page have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust 

      1. SUB-TYPE OF MDS: MDS with 10% or more bone marrow blasts; also acute myeloid leukaemia
      2. SEVERITY OF MDS: Intermediate – 2 or High Risk
      3. NAME OF DRUG: Mylotarg, AC220 (a novel drug that blocks the action of a gene – FLT3, which is important in the growth of blood cells
  1. Aims and benefits: This trial is designed for patients over 60 years considered fit for intensive chemotherapy. It aims to answer several therapeutic questions.
    • To determine if a new dosing schedule of Mylotarg (two doses) is better than the current standard of a single dose.
      Does adding AC220 improve outcomes.
    • Is monitoring minimal residual disease (MRD) after completing course 1 of chemotherapy (by regular bone marrow biopsies) of clinical value.
    • To compare the effectiveness of two different chemotherapy regimens (Daunorubicin + high dose Cytarabine vs Intermediate dose Cytarabine) when used as course 3 of chemotherapy.
    • To assess the value of a reduced intensity allogeneic stem cell transplant in maintaining remission.
  2. Basic inclusion criteria:
    • Acute myeloid leukaemia (excluding acute promyelocytic leukaemia) or high risk Myelodysplastic Syndrome (>10% bone marrow blasts)
    • Over the age of 60, but patients under this age are eligible if they are not considered eligible for the AML 19 trial
    • Suitable for intensive chemotherapy
    • Adequate kidney function
  3. Basic exclusion criteria:
    • Patients who previously received demethylation treatment (eg. Azacitidine) for high risk MDS (>10% blasts)
      Previous chemotherapy for acute myeloid leukaemia
    • Concurrent active malignancy excluding basal cell carcinoma
    • Pregnant or lactating
    • Known infection with human immunodeficiency virus (HIV)
  4. Trial sites/locations and name of physician in charge of trial: 
    • Aberdeen Royal Infirmary
    • Blackpool Victoria Hospital
    • Derriford Hospital (Plymouth Hospital)
    • Ninewells Hospital
    • Poole General Hospital
    • Queen Alexandra Hospital (Portsmouth)
    • St Helier Hospital
    • University College London Hospital
    • University Hospital of Wales
    • NHS Lanarkshire (Monklands, Wishaw and Hairmyres Hospital)
    • Christie Hospital
    • Stafford Hospital
    • Nottingham
    • Royal Free Hospital
    • Raigmore Hospital
    • Russells Hall Hospital
    • New Victoria Hospital
    • Victoria Hospital (Kirkcaldy)
    • Birmingham Heartland Hospital
    • Salisbury District Hospital
    • Kettering General Hospital
    • Bristol Haematology & Oncology Centre
    • Crosshouse Hospital (Ayrshire and Arran Health Board)
    • Ayr Hospital (Ayrshire and Arran Health Board)
    • Basingstoke and North Hampshire Hospital
    • Beatson General Hospital (Gartnavel General Hospital)
    • Manchester Royal Infirmary
    • Hillingdon Hospital
    • Torbay District General Hospital
    • Lincoln County Hospital
    • Salford Royal Hospital
    • Western General Hospital
    • Royal Bournemouth General Hospital
    • Royal Cornwall Hospital (Treliske)
    • Aintree University Hospital
    • Ysbyty Gwynedd Hospital
    • Queen's Hospital, Romford
    • Ysbyty Glan Clwyd
    • Arrowe Park Hospital (Wirral)
    • Royal Liverpool University Hospital
    • Musgrove Park Hospital (Taunton & Somerset Hospital)
    • Southampton General Hospital
    • Rigshospitalet University Hospital
    • Roskilde Hospital
    • Countess Of Chester Hospital
    • Aalborg Hospital
    • Herlev University Hospital
    • Leeds Teaching Hospital NHS Trust (St James)
    • University Hospital Odense
    • Royal Stoke University Hospital
    • Castle Hill Hospital
    • University Hospitals Coventry and Warwickshire (UHCW, Coventry)
    • Cheltenham General Hospital
    • Royal Devon & Exeter Hospital
    • Worcestershire Acute Hospitals NHS Trust
    • Queen Elizabeth Hospital Birmingham
    • Great Western Hospital
    • Leicester Royal Infirmary
    • Aarhus University Hospital
    • Churchill Hospital
    • Freeman Hospital
    • Whiston Hospital & St Helens
    • Addenbrooke's Hospital
    • St Bartholomew's Hospital
    • Royal Marsden
    • Bradford Royal Infirmary
    • Guy's Hospital
    • James Cook University Hospital
    • Milton Keynes University Hospital
    • Singleton Hospital
  5. More information:

Please read information and always discuss trial information with your own physician.

Paper of the Month

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Visit our archives

IPSS-R MDS Risk Assessment Calculator

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator

calculator

Click here

MDS Fact Sheet

MDS Factsheet for GPs General Practicioners

MDS Fact Sheet

Click here

Varicella Vaccine in MDS

Urgent Clarification on varicella vaccine policy

Current advice from the UK MDS Forum is not to give the Live Varicella Vaccine to patients with MDS.

Please read below correspondence between Professor Salisbury and Dr George Follows, the latter on behalf of the CLL Forum, on the varicella vaccine policy.
This is an external link to the British Society for Haematology  Click here

NICE Guideline

Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.

NICE logo

Click here

BSH Guidelines

This is an external link to the home of the British Society for Haematology (BSH). 

BSH Logo Strapline RGB

Click here